Skip to main content

Tagged With "Exhaled nitric oxide"

Blog Post

Aetna Decides FeNO Testing Is Medically Necessary for Its Members With Asthma

AAFA Community Services ·
Circassia Pharmaceuticals, Inc., a specialty pharmaceutical company focused on respiratory disease, is pleased to announce that Aetna, one of the largest health insurance companies in the United States, has updated its Exhaled Breath Tests Clinical Policy to include the measurement of exhaled nitric oxide as “medically necessary” for the evaluation of asthma and for monitoring the response to long-term control therapy.
Blog Post

FDA Approves Dupixent® for Treatment of Asthma

AAFA Community Services ·
The FDA has approved another biologic treatment, Dupixent, for the treatment of both moderate and severe asthma patients with eosinophilic phenotype and oral corticosteroid-dependent asthma, regardless of phenotype.
Blog Post

FDA Grants Breakthrough Therapy Designation for Tezepelumab for Severe Asthma

AAFA Community Services ·
AstraZeneca and its partner Amgen Inc. (Amgen) announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for tezepelumab in patients with severe asthma, without an eosinophilic phenotype, who are receiving inhaled corticosteroids/long-acting beta2-agonists with or without oral corticosteroids and additional asthma controllers.
Blog Post

FeNO Testing Can Be a Helpful Part of Asthma Management

AAFA Community Services ·
Asthma is a chronic disease that causes your airways to be inflamed. The most common symptoms of asthma are coughing, shortness of breath, wheezing and chest tightness. But there are other diseases that can have the same symptoms of asthma. For your doctor to make the right diagnosis, it is important to know if your airways are inflamed.
Blog Post

Global Initiative for Asthma (GINA) Recommends the Use of Fractional Exhaled Nitric Oxide (FeNO) Monitoring for Difficult-to-Treat and Severe Asthma Management

AAFA Community Services ·
Circassia Pharmaceuticals, Inc. (“Circassia” or “the Company”), a specialty pharmaceutical company focused on respiratory disease, today announced that Fractional Exhaled Nitric Oxide (FeNO) monitoring is recommended in the latest Global Initiative for Asthma (GINA) guide, “Difficult-to-Treat & Severe Asthma in Adolescent and Adult Patients – Diagnosis and Management.”
Comment

Re: Aetna Decides FeNO Testing Is Medically Necessary for Its Members With Asthma

JillS ·
Thank goodness . I hated fighting with insurance every time it was ordered by pulmonary!
Comment

Re: Aetna Decides FeNO Testing Is Medically Necessary for Its Members With Asthma

Melissa G ·
Jill, glad to hear this will help you. How often have you had the FeNO testing done?
Blog Post Featured

Asthma Diagnosis, Management, and Treatment in the U.S. Is Changing – What the New Guidelines Say

AAFA Community Services ·
On Dec. 3, 2020, the National Institutes of Health (NIH) announced updates to the clinical guidelines used to diagnose and manage asthma. The new guidelines are titled "The 2020 Focused Updates to the Asthma Management Guidelines: A Report from The National Asthma Education and Prevention Program Expert Panel Working Group." The National Heart, Lung, and Blood Institute (NHLBI), part of the NIH, oversaw the National Asthma Education and Prevention Program Coordinating Committee (NAEPPCC) and...
Blog Post

Amgen Submits Biologics License Application for Tezepelumab for Severe Asthma

AAFA Community Services ·
Amgen today announced its partner AstraZeneca submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for tezepelumab, a potential first-in-class medicine in severe asthma.
Post
×
×
×
×